19 July, 2019
Clarification of the statement in the interim report published 19 July 2019 regarding the rights issue with pre-emptive rights
Karo Pharma Aktiebolag (”Karo Pharma”) today published its interim report for the period January – June 2019. On page 2 of the Swedish language version of the interim report, it was, slightly misleadingly, stated that a directed rights issue of approximately MSEK 1,500 with pre-emptive rights for the shareholders of Karo Pharma is planned. Karo...
Read more
19 July, 2019
INTERIM REPORT JANUARY – JUNE 2019
THE PERIOD AND THE SECOND QUARTER
Read more
21 June, 2019
Karo Pharma acquires Trimb for MSEK 3,400 and intends to carry out a rights issue of approximately MSEK 1,500
Karo Pharma AB (publ) (the ”Company” or ”Karo Pharma”) has today acquired all the shares of Trimb Holding AB (“Trimb”) from Avista Capital Partners (“Avista”) and other shareholders for MSEK 3,400 (the ”Transaction”). The Transaction is expected to contribute positively to Karo Pharma’s market position and create a strong platform for Karo Pharma’s continued growth....
Read more
16 May, 2019
ANNUAL GENERAL MEETING 2019 IN KARO PHARMA AKTIEBOLAG
At today’s annual general meeting of Karo Pharma, the following decisions were passed. The annual general meeting resolved to adopt the income statement and balance sheet for the group and the parent company. The annual general meeting resolved that available funds, including the earnings for the year, were to be carried forward. The annual general...
Read more
26 April, 2019
INTERIM REPORT THE FIRST QUARTER 2019
· Net sales amounted to MSEK 420.8 (267.1). This corresponds to an increase of 58%. The growth is attributable to products acquired during the period. · Net sales decreased by 6% compared to pro forma numbers for the same period 2018. At comparable exchange rates, sales decreased by 8%. The decrease in net sales is...
Read more
16 April, 2019
NOTICE OF ANNUAL GENERAL MEETING IN KARO PHARMA AKTIEBOLAG
The shareholders of Karo Pharma Aktiebolag, reg. no. 556309-3359, are given notice of the annual general meeting to be held at 14:00 CET on 16 May 2019, at Näringslivets Hus, Storgatan 19 in Stockholm.
Read more
9 April, 2019
Karo Pharma publishes the 2018 annual report
Karo Pharma publishes its annual report for 2018. Today, on 9 April 2019, Karo Pharma is publishing its annual report for 2018 on the company’s website, www.karopharma.com (http://%20www.karopharma.com). FOR ADDITIONAL INFORMATION, PLEASE CONTACT: Mats-Olof Wallin, CFO, +4676 002 60 10, mats-olof.wallin@karopharma.se ABOUT KARO PHARMA Karo Pharma is a Specialty Pharma company, which develops and markets products for pharmacies...
Read more
9 April, 2019
New date for the annual general meeting of Karo Pharma
STOCKHOLM on 9 April 2019
Read more
3 April, 2019
Christoffer Lorenzen appointed CEO of Karo Pharma; Peter Blom resigning.
The Board of Karo Pharma Aktiebolag (publ) (“Karo Pharma”) has appointed Christoffer Lorenzen as the new CEO of Karo Pharma, replacing Peter Blom. Christoffer will take on his new position on July 1, 2019. Up until this date, and effective as of today, Ulf Mattsson assumes the CEO position on an interim basis. Karo Pharma...
Read more
14 February, 2019
YEAR-END REPORT 2018
FULL YEAR AND THE FOURTH QUARTER · Net sales amounted to MSEK 1,615.1 (657.6), of which the fourth quarter amounted to MSEK 463.3 (238.7). This corresponds to an increase of 146% for the full year, and 94% for the fourth quarter. A large part of the growth is attributable to products acquired during the period....
Read more
11 February, 2019
Karo Intressenter’s proposals ahead of the Extraordinary General Meeting in Karo Pharma on 14 February 2019
EQT VIII[1] through Karo Intressenter AB (”Karo Intressenter”) proposes, ahead of the Extraordinary General Meeting in Karo Pharma Aktiebolag (”Karo Pharma”) on 14 February 2019 that the Board Member Håkan Åström is reelected and that Bo Jesper Hansen, Erika Henriksson, Vesa Koskinen, Christoffer Lorenzen and Åsa Riisberg are elected as new Board Members with Bo Jesper Hansen as Chairman of the Board.
Read more
2 January, 2019
STATEMENT BY THE BOARD OF DIRECTORS OF KARO PHARMA AKTIEBOLAG IN RELATION TO THE INCREASED PUBLIC OFFER FROM EQT VIII, THROUGH KARO INTRESSENTER AB
The Board of Directors of Karo Pharma Aktiebolag has concluded to unanimously recommend that the shareholders of Karo Pharma Aktiebolag accept the increased public offer made by EQT VIII, through Karo Intressenter AB.
Read more
